Kodiak Sciences rises after eye-disease drugs meet late-stage trial goals

Kodiak Sciences

28/09/2026 15:05

Updates
** Shares of drug developer Kodiak Sciences KOD.O jump 141.1% to $78, hitting highest level in more than four years
** Stock set for biggest daily percentage rise ever, if gains hold
** Co says its experimental drugs Zenkuda and tabirafusp-ted met the main goals of a late-stage trial in patients with wet age-related macular degeneration
** Both drugs achieved vision gains at one year that were not inferior to aflibercept, the comparison treatment
** Wet age-related macular degeneration causes abnormal blood vessels to leak beneath the retina and can lead to loss of central vision
** About 54% of Zenkuda patients reached a six-month dosing interval, potentially reducing the number of eye injections needed
** Both drugs showed safety broadly consistent with aflibercept; Kodiak plans further analyses to identify which patients may benefit most from tabirafusp-ted
** Co plans to seek US approval for Zenkuda in Q4 2026, using results from five successful late-stage studies across three retinal diseases
** Including session's move, KOD up 174.4% YTD

 (Reporting by Kunal Das in Bengaluru)
 ((Kunal.Das2@thomsonreuters.com;))